Grafapex
Payments companies reported to CMS as associated with Grafapex. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Grafapex, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Grafapex
These are the largest totals companies reported as associated with Grafapex. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Filippo Milano | Seattle, WA | Hematology & Oncology | $6,137.56 |
| Mhd Monzr Al Malki | Duarte, CA | Hematology (Internal Medicine) | $4,760.00 |
| Eneida Nemecek | Portland, OR | Pediatric Hematology-Oncology | $2,040.00 |
| Michael Eckrich | Madison, WI | Pediatric Hematology-Oncology | $222.98 |
| Rachel Phelan | Milwaukee, WI | Pediatric Hematology-Oncology | $210.32 |
| Sameem Abedin | Milwaukee, WI | Hematology & Oncology | $169.48 |
| Hassan Alkhateeb | Rochester, MN | Hematology & Oncology | $169.48 |
| Wilson Vasconez Samaniego | Baltimore, MD | Pediatric Hematology-Oncology | $169.48 |
| Vivek Roy | Jacksonville, FL | Hematology & Oncology | $169.47 |
| Michael Verneris | Aurora, CO | Pediatric Hematology-Oncology | $164.88 |
Prescribed Grafapex?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.